Navigation Links
OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
Date:3/17/2010

ROCKVILLE, Md., March 17 /PRNewswire/ --  OriGene Technologies, Inc., a leading gene-centric life sciences company, announced the completion of a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. OriGene's previous investors Morningside Venture Investments and President International Development Corp. (PIDC) also participated in this round.  The proceeds from the funding will be used to continue to build OriGene's TrueMAB™ monoclonal antibody collection.  

"We are delighted by this vote of confidence from our existing and new investors and share their enthusiasm for our growth strategy and execution.  The funding will propel us closer to meeting our goal of building the largest monoclonal antibody collection in the world covering the entire human genome of approximately 20,000 genes," said Wei-Wu He, OriGene's Chairman and Chief Executive Officer.

The TrueMAB™ Collection of monoclonal antibodies will be developed with the most up-to-date antibody technologies and will be significantly different from many antibodies on the market, as OriGene will be using authentic human full-length proteins as immunogens during the manufacturing process. OriGene has dedicated the last decade to build the largest collection of human full-length cDNA clones in the world. The collection has enabled OriGene to manufacture human full-length proteins directly from human cells for producing monoclonal antibodies. TrueMAB™ monoclonal antibodies generated by authentic human antigen, have been proven far superior in quality than traditional small peptide generated monoclonal and polyclonal antibodies, especially in applications such as flow cytomery and multiplex ELISA assays. Many of these monoclonal antibodies are currently available and will be utilized by multiple commercial partners for various applications.

About OriGene Technologies

OriGene Technologies, Inc., is a gene centric life sciences tool company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery.  OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB), 100,000 highly validated human tissues, and Luminex Multiplex Assay Products.  OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. OriGene is committed to its mission to be "Your Gene Company;" in supplying everything a researcher would need for gene based research. For more information, visit www.origene.com.

SOURCE OriGene Technologies, Inc.

Back to top

RELATED LINKS
http://www.origene.com

'/>"/>

SOURCE OriGene Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OriGene Technologies Acquires Marligen Biosciences
2. OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells
3. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
4. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
5. DHS Technologies Launches VTAP 2.0
6. DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger
7. OrthoAccel Technologies, Inc. Selected to Pitch at the 2010 WBTshowcase
8. Netsmart Technologies Selected by Douglas Gardens Community Mental Health to Provide Behavioral Health Software Solution
9. China Medical Technologies Reports Third Fiscal Quarter Financial Results
10. Doctors and First Responders Rely on Oberthur Technologies in Times of Emergency
11. Fortrex Technologies Achieves HITRUST Common Security Framework Assessor Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):